StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$44.89−1.96 (-4.18%)

Close on Nov 18, 2026Market cap $3.29BP/E –Yield –

Enliven Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Enliven Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$66.94M. For fiscal 2025 it was -$70.30M. The highest annual figure on record is -$21.88M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$70.30M–
FY2024Dec 31, 2024-$73.19M–
FY2023Dec 31, 2023-$61.27M–
FY2022Dec 31, 2022-$32.08M–
FY2021Dec 31, 2021-$46.77M–
FY2020Dec 31, 2020-$37.40M–
FY2019Dec 31, 2019-$21.88M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.53M–
Q1 FY2026Mar 31, 2026-$19.29M–
Q4 FY2025Dec 31, 2025-$15.84M–
Q3 FY2025Sep 30, 2025-$13.28M–
Q2 FY2025Jun 30, 2025-$17.06M–
Q1 FY2025Mar 31, 2025-$24.13M–
Q4 FY2024Dec 31, 2024-$17.20M–
Q3 FY2024Sep 30, 2024-$12.19M–
Q2 FY2024Jun 30, 2024-$20.44M–
Q1 FY2024Mar 31, 2024-$23.36M–
Q4 FY2023Dec 31, 2023-$12.48M–
Q3 FY2023Sep 30, 2023-$15.89M–
Q2 FY2023Jun 30, 2023-$12.05M–
Q1 FY2023Mar 31, 2023-$20.84M–
Q4 FY2022Dec 31, 2022-$8.15M–
Q3 FY2022Sep 30, 2022-$6.45M–
Q2 FY2022Jun 30, 2022-$7.12M–
Q1 FY2022Mar 31, 2022-$10.36M–
Q4 FY2021Dec 31, 2021-$12.49M–
Q3 FY2021Sep 30, 2021-$10.90M–
Q2 FY2021Jun 30, 2021-$10.37M–
Q1 FY2021Mar 31, 2021-$13.02M–
Q4 FY2020Dec 31, 2020-$8.27M–
Q3 FY2020Sep 30, 2020-$10.35M–
Q2 FY2020Jun 30, 2020-$9.26M–
Q1 FY2020Mar 31, 2020-$9.53M–
Q4 FY2019Dec 31, 2019-$8.04M–
Q3 FY2019Sep 30, 2019-$6.28M–
Q2 FY2019Jun 30, 2019-$5.15M–
Q1 FY2019Mar 31, 2019-$2.41M–

More Enliven Therapeutics figures

See a number that looks wrong?